| h-debate-6d024835a85 | Circadian SPM Synthesis Restoration | 0.00 | 0.55 | CLOCK, BMAL1, ALOX15 | proposed | 2026-04-29 | sda-2026-04-01-gap-014 |
| h-debate-34ee7cde288 | Epigenetic SPM Pathway Reprogramming | 0.00 | 0.55 | DNMT1, HDAC2 | proposed | 2026-04-29 | sda-2026-04-01-gap-014 |
| h-debate-cfd3d2d7931 | Cannot Generate Hypotheses | 0.00 | 0.55 | N/A | proposed | 2026-04-29 | sda-2026-04-01-gap-9137255b |
| h-debate-4112ce83fa9 | CRISPR-dCas9 Epigenetic Reprogramming of Stress Granules | 0.00 | 0.55 | TDP43 + FUS | proposed | 2026-04-29 | sda-2026-04-01-002 |
| h-debate-6b41b68e47b | Mitochondrial-Lysosomal Contact Site Modulators | 0.00 | 0.55 | VDAC1 + LAMP1 | proposed | 2026-04-29 | sda-2026-04-01-002 |
| h-debate-ca4b31f76b1 | Engineered Extracellular Vesicle Therapy with Synthetic Biology | 0.00 | 0.55 | GBA + HSP70 + LAMP2A | proposed | 2026-04-29 | sda-2026-04-01-002 |
| h-debate-58aa0aeaa66 | Pharmacological Chaperone-Mediated Selective Autophagy | 0.00 | 0.55 | GBA + SQSTM1 | proposed | 2026-04-29 | sda-2026-04-01-002 |
| h-debate-63f66fbf6fa | Temporal Metabolic Rewiring with Circadian Modulators | 0.00 | 0.55 | NR1D1 + CLOCK + TFEB | proposed | 2026-04-29 | sda-2026-04-01-002 |
| h-debate-9ee6e75a400 | Lipid Raft Disruptors with Membrane Fluidizers | 0.00 | 0.55 | GBA + SNCA | proposed | 2026-04-29 | sda-2026-04-01-002 |
| h-debate-822f893c3e0 | Selective Glucosylceramide Synthase Inhibition with Lysosomal Enhancement | 0.00 | 0.55 | UGCG + TFEB | proposed | 2026-04-29 | sda-2026-04-01-002 |
| h-debate-2cfb0990126 | Qualitative research integration enhances patient-centered neurodegeneration stu | 0.00 | 0.55 | N/A - qualitative methodology | proposed | 2026-04-29 | sda-2026-04-01-gap-auto-fd6b1635d9 |
| h-debate-bbe333ca21a | Power analysis optimization reduces false negatives in neurodegeneration trials | 0.00 | 0.55 | N/A - statistical methodology | proposed | 2026-04-29 | sda-2026-04-01-gap-auto-fd6b1635d9 |
| h-debate-78bb6479d31 | Standardized qPCR protocols improve neurodegeneration biomarker reproducibility | 0.00 | 0.55 | N/A - methodological intervention | proposed | 2026-04-29 | sda-2026-04-01-gap-auto-fd6b1635d9 |
| h-debate-1ac93d6e5c2 | Sleep-Dependent Synaptic Plasticity Restoration | 0.00 | 0.55 | N/A (Plasticity Networks) | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-18cf98ca |
| h-debate-ef41473f123 | Metabotropic Glutamate Receptor-Based Sleep Stabilization Therapy | 0.00 | 0.55 | GRM5 | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-18cf98ca |
| h-debate-35185d474ec | Circadian-Metabolic Coupling for Neuroprotection | 0.00 | 0.55 | CLOCK/BMAL1 | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-18cf98ca |
| h-debate-f42425b5b75 | Trauma-Induced Sleep Disruption as Therapeutic Window | 0.00 | 0.55 | N/A (Sleep Systems) | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-18cf98ca |
| h-debate-0c167479fbf | Biofluid-Guided Predictive Sleep Intervention | 0.00 | 0.55 | N/A (Biomarker Panel) | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-18cf98ca |
| h-debate-c017235110f | Glymphatic Enhancement Through Controlled Sleep Depth Modulation | 0.00 | 0.55 | N/A (Sleep Architecture) | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-18cf98ca |
| h-debate-e9062cec160 | Chronotherapeutic Orexin Modulation for Tau Clearance | 0.00 | 0.55 | HCRTR1/HCRTR2 | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-18cf98ca |
| h-debate-44c554c8661 | Compensatory RBP Expression Therapy | 0.00 | 0.55 | ELAVL1 | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-68d9c9c1 |
| h-debate-d311450401b | Mitochondrial RNA Processing Enhancement | 0.00 | 0.55 | LRPPRC | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-68d9c9c1 |
| h-debate-c31c367bbbe | RNA Modification Enzyme Modulation | 0.00 | 0.55 | METTL3 | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-68d9c9c1 |
| h-debate-c6005bc2428 | Cross-Disease RNA Granule Dissolution Therapy | 0.00 | 0.55 | G3BP1 | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-68d9c9c1 |
| h-debate-9531e908c33 | Proteostasis Network Activation for RBPs | 0.00 | 0.55 | HSPA1A | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-68d9c9c1 |
| h-debate-0425e09671f | RNA Splicing Corrector Compounds | 0.00 | 0.55 | TARDBP | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-68d9c9c1 |
| h-debate-b1eb50b5e4e | Astrocyte Priming Therapy for Preconditioning Neuroprotection | 0.00 | 0.55 | GFAP | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-89432b95 |
| h-debate-166187b528e | Fatty Acid Metabolism Enhancers for Activity-Dependent Neurodegeneration | 0.00 | 0.55 | CPT1A | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-89432b95 |
| h-debate-0d42b94d251 | LRP1-ARF1 Lactylation Inhibitors for Metabolic Neuroprotection | 0.00 | 0.55 | ARF1 | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-89432b95 |
| h-debate-d86d79b9d94 | TAK1 Pathway Modulators for Hypothalamic Metabolic Disorders | 0.00 | 0.55 | MAP3K7 | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-89432b95 |
| h-debate-ccbced20c91 | Mitochondrial Transfer Enhancers for Synaptic Dysfunction | 0.00 | 0.55 | MIRO1 | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-89432b95 |
| h-debate-51c4248ae68 | CD38 Agonist Therapy for Alzheimer's Disease | 0.00 | 0.55 | CD38 | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-89432b95 |
| h-debate-8c3d8c6d1a9 | Ginsenoside Rb1 Analogs for Complex I-Mediated Neuroprotection | 0.00 | 0.55 | NDUFS1 | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-89432b95 |
| h-debate-42a75b89701 | Epigenetic Clock Reversal Through Targeted DNA Demethylation | 0.00 | 0.55 | DNMT1 | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-bc5f270e |
| h-debate-d2fa5138b6c | Temporal Epigenetic Clock Synchronization Therapy | 0.00 | 0.55 | CLOCK | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-bc5f270e |
| h-debate-01c9c9962d7 | Protein Aggregation-Epigenetic Stress Response Modulation | 0.00 | 0.55 | PSMD1 | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-bc5f270e |
| h-debate-bfe1b83aa19 | Inflammaging-Epigenome Decoupling Strategy | 0.00 | 0.55 | NFKB1 | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-bc5f270e |
| h-debate-d028b27e4d0 | Mitochondrial-Nuclear Epigenetic Communication Restoration | 0.00 | 0.55 | SOD2 | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-bc5f270e |
| h-debate-0b950b4ed02 | Epigenetic Clock Biomarker-Guided Combination Therapy | 0.00 | 0.55 | Multiple (SIRT1, MTOR, NFKB1) | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-bc5f270e |
| h-debate-334658fce29 | NAD+ Metabolic Rescue Via Autophagy-Epigenetic Coupling | 0.00 | 0.55 | SIRT1 | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-bc5f270e |
| h-debate-99e31e7ddb3 | Anti-CAA Immunotherapy for Glymphatic Rescue | 0.00 | 0.55 | APP, PSEN1, C1QA | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-ee5a5023 |
| h-debate-b1fcf8fa0bf | Arteriolosclerosis-Targeted Perivascular Space Restoration | 0.00 | 0.55 | ACTA2, COL4A1, MMP9 | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-ee5a5023 |
| h-debate-97553319570 | Perivascular Inflammation Resolution Therapy | 0.00 | 0.55 | TREM2, AQP4, C1QA | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-ee5a5023 |
| h-debate-e123259d9f9 | Chronotherapeutic Glymphatic Enhancement | 0.00 | 0.55 | CLOCK, ARNTL, PER2, CRY1 | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-ee5a5023 |
| h-debate-c6e5ca34453 | Dual Proteinopathy Clearance via Enhanced Drainage | 0.00 | 0.55 | ACTA2, PDGFRB, PROX1 | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-ee5a5023 |
| h-debate-76b52c1666e | Circadian Melatonin Therapy for Glymphatic Enhancement | 0.00 | 0.55 | MTNR1A, MTNR1B, CLOCK, ARNTL | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-ee5a5023 |
| h-debate-1e511c421d9 | Sleep Architecture Optimization via Glymphatic Pacing | 0.00 | 0.55 | GABRA1, ADORA1, ADRA2A | proposed | 2026-04-29 | sda-2026-04-01-gap-v2-ee5a5023 |
| h-debate-f74e7f8e196 | Akkermansia muciniphila Metabolite Inhibition | 0.00 | 0.55 | Akkermansia_Mucinase | proposed | 2026-04-29 | sda-2026-04-01-gap-20260401-225149 |
| h-debate-eb3d3ffc951 | Circadian-Synchronized Microbiome Intervention | 0.00 | 0.55 | CLOCK | proposed | 2026-04-29 | sda-2026-04-01-gap-20260401-225149 |
| h-debate-7199453b125 | Mediterranean Diet Metabolite Synthesis via Engineered Probiotics | 0.00 | 0.55 | Custom_Metabolic_Pathway | proposed | 2026-04-29 | sda-2026-04-01-gap-20260401-225149 |